Marisa Wexler, MS,  senior science writer—

Orkambi (ivacaftor/lumacaftor) can improve glucose tolerance in people with cystic fibrosis, a small study in patients either at risk of or newly diagnosed with diabetes suggests. The study, “Effect of one-year lumacaftor–ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients,” was published in the …

Supplemental estrogen, most commonly taken for contraception, is associated with poorer bone mineral density in people with cystic fibrosis (CF), a new study suggests. The study, “Oral ethinyl estradiol treatment in women with cystic fibrosis is associated with lower bone mineral density,” was published in the …

A measure called the lung clearance index (LCI) can predict low blood oxygen levels during sleep in people with cystic fibrosis (CF) better than conventional assessments of lung function, a study suggests. The study, “Lung clearance index evaluation in detecting nocturnal hypoxemia in cystic fibrosis patients:…

Delivering nutrients through dialysis could help people with co-occurring cystic fibrosis (CF) and kidney disease meet their nutritional requirements, a recent case report illustrates. The report, “Intradialytic parenteral nutrition improves nutritional status in a complex cystic fibrosis patient with redo double lung transplant and end-stage renal…

An unusual clinical presentation can hinder proper diagnosis for people with cystic fibrosis (CF), even with newborn screening, a new case report contends. The report, “Uncommon clinical presentation of cystic fibrosis in a patient homozygous for a rare CFTR mutation: a case report,” was published in…

Liver ultrasounds can help identify children with cystic fibrosis (CF) who are at higher risk of developing liver disease, a new study shows. The study, “Heterogeneous Liver on Research Ultrasound Identifies Children with Cystic Fibrosis at High Risk of Advanced Liver Disease: Interim Results of a…

The U.S. Food and Drug Administration (FDA) has granted fast track designation to MRT5005, an investigational RNA-based treatment for cystic fibrosis (CF), the therapy’s developer, Translate Bio, has announced. Fast track is given to medications that aim to treat serious or life-threatening conditions and…

Enrollment is complete for a European initiative to test an organoid-based, personalized-medicine approach to treating cystic fibrosis, with the first trial starting later this year, said Proteostasis Therapeutics (PTI) and CF Europe. The Human Individualized Therapy of CF (HIT-CF) initiative will test PTI drug combinations through…

The genetic programming that causes embryonic cells to differentiate into lung cells was described for the first time in a study in mice. Researchers say that understanding the genetic changes necessary for lung cell development could allow for more effective use of stem cells in research and treatment. The study,…

Enrollment is nearing completion for two Phase 2 clinical trials testing the experimental treatment ELX-02 in people with cystic fibrosis (CF), according to Eloxx Pharmaceuticals, the company developing ELX-02. “We expect full enrollment to be achieved during the first quarter of 2020, and to report topline results…